An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs AZD 9496 (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 11 Oct 2017 Planned End Date changed from 5 Dec 2018 to 30 Nov 2018.
- 11 Oct 2017 Planned primary completion date changed from 5 Dec 2018 to 30 Nov 2018.
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.